Training activity information
Details
Interpret and report on a range of genetic testing in solid tumours, to include:
- Ovarian
- Colorectal cancer
Type
Developmental training activity (DTA)
Evidence requirements
Evidence the activity has been undertaken by the trainee.
Reflection on the activity at one or more time points after the event including learning from the activity and/or areas of the trainees practice for development.
An action plan to implement learning and/or to address skills or knowledge gaps identified.
Reflective practice guidance
The guidance below is provided to support reflection at different time points, providing you with questions to aid you to reflect for this training activity. They are provided for guidance and should not be considered as a mandatory checklist. Trainees should not be expected to provide answers to each of the guidance questions listed.
Before action
- What are the key genetic alterations relevant to ovarian and colorectal cancer and their implications for diagnosis, prognosis, and targeted therapies?
- What are the established guidelines and best practices for interpreting and reporting these types of genetic results, including variant classification and clinical significance?
- What are the typical components of a genetic report for solid tumours, and what information is crucial for clinicians involved in patient care?
- How will you develop your skills in correlating genetic findings with clinical and pathological information for accurate interpretation?
- Will you review example genetic reports for ovarian and colorectal cancer with your training officer or a senior colleague?
- What resources (e.g., relevant literature, variant databases, reporting guidelines) will you consult to prepare for interpretation and reporting?
- What potential challenges might you anticipate in interpreting and reporting results for solid tumours (e.g., low-level mosaicism, complex mutation profiles)? How might you approach these?
In action
- How are you currently evaluating specific biomarkers, and what real-time decisions are you making to determine their clinical actionability and frame their relevance for treatment and patient management in your report?
- What challenges are you encountering in this moment—such as interpreting large gene panels, resistance mechanisms, or addressing the implications of germline findings in somatic testing—and how effectively are you translating this complex data for oncologists?
- How are you managing ambiguity or novelty, for instance by researching the functional significance of rare variants or consulting with a molecular pathologist or the MDT, to ensure your report provides clear, contextualised recommendations aligned with precision oncology guidelines?
On action
- What key genetic alterations did you highlight in your reports for ovarian and colorectal cancer cases?
- How did you convey the prognostic and predictive implications of these findings?
- Were there any challenges in interpreting variant pathogenicity or clinical significance?
- Did you enhance your skills in interpreting genetic data relevant to solid tumours like ovarian and colorectal cancer?
- Did you learn about the specific reporting requirements and guidelines for these tumour types?
- How do you address uncertainty or limitations in your interpretation and reporting?
- What resources will you consult to aid in the interpretation of complex somatic variants?
- How will you ensure that your reports are tailored to the needs of the requesting clinician?
- What role does variant curation play in the interpretation and reporting process?
Beyond action
- Reflecting on your initial experiences interpreting and reporting on genetic testing in ovarian and colorectal cancer, how has your ability to contextualise genetic findings with clinical information improved?
- Have you become more adept at handling challenging scenarios, such as incidental findings or variants of uncertain significance, in your reports?
- How have the reporting skills developed here been transferable to your reporting on other types of genetic tests or in different clinical specialties?
- With the increasing use of complex genomic reports in solid tumour management, how will your foundational interpretation and reporting skills enable you to effectively communicate relevant information to clinicians in the future?
Relevant learning outcomes
| # | Outcome |
|---|---|
| # 3 |
Outcome
Analyse, interpret and report tests for patients referred with sporadic cancer. |